Recombinant Lactobacillus Oral Vaccine for African Swine Fever

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is no commercial vaccine available for African swine fever (ASF), and existing prevention methods cannot guarantee complete protection against virus contact.

Innovation Solution

A recombinant vector containing immunogenic proteins p72 and p54 of the African swine fever virus is used to construct a Lactobacillus expression system, which is then used to create an oral live bacteria preparation to block virus infection.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If biosafety prevention and control method is used to block contact between virus and organism, then safety is improved, but complete protection cannot be guaranteed

Engineering Contradiction:

Improveprotection effectivenessVSAvoidvirus contact risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies preliminary action by administering the oral preparation containing recombinant Lactobacillus expressing ASFV immunogenic proteins before virus exposure. The Lactobacillus colonizes the gastrointestinal tract and mucous membranes in advance, creating a protective barrier that prevents virus attachment and entry, thus providing proactive protection rather than reactive treatment

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent uses recombinant Lactobacillus as an intermediary between the host organism and the ASFV. The Lactobacillus expresses immunogenic proteins that act as decoys, binding to the virus and preventing it from interacting with host cells. This intermediary approach creates a biological buffer that enhances protection while maintaining safety

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If oral live bacteria preparation is used to block virus infection, then effectiveness and speed are improved, but device complexity increases

Engineering Contradiction:

Improveinfection blocking effectivenessVSAvoidrecombinant expression system complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies self-service by designing a self-replicating oral preparation system. The recombinant Lactobacillus expresses immunogenic proteins autonomously after oral administration, utilizing its own metabolic machinery to produce and secrete protective proteins at the infection site. This eliminates the need for external production and delivery infrastructure, simplifying the overall system while maintaining high effectiveness

Inventive Principle:

Principle #25Self-service

Solution Approach 2:

The patent extracts only the essential immunogenic protein sequences (p72 and p54) from the complex ASFV genome and inserts them into a simple Lactobacillus expression vector. This extraction approach isolates the critical protective elements while discarding unnecessary viral complexity, resulting in a streamlined recombinant system that is easier to manufacture and deploy

Inventive Principle:

Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The oral live bacteria preparation effectively blocks virus infection by forming an antigen protein biofilm on the mucous membrane, preventing the virus from binding to target cells, and is safer, more effective, and faster than traditional vaccines.

Implementation Method 1

A recombinant vector containing immunogenic protein of African swine fever virus, wherein the recombinant vector takes Lactobacillus expression vector pVE5523 as basic vector, and the nucleotide sequence encoding the immunogenic protein of African swine fever virus is cloned between EcoRV and SalI restriction sites of the basic vector

Methodology Applied

Scientific EffectGene recombination:

Implementation Method 2

construct a Lactobacillus expression system expressing p72 and p54 proteins of African swine fever virus

Methodology Applied

Scientific EffectProtein expression:

Implementation Method 3

The antigen protein can be combined with the virus binding site on the target cells to seal the virus receptor protein site on the mucous membrane surface, thus playing the role of ecological occupation. When the live viruses in the environment invade the body, the virus binding site on the target cell has been completely blocked by antigen protein biofilm, and the virus can not bind to the virus binding site on the target cell

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS12297445B2Recombinant vector containing immunogenic protein of African swine fever virus, recombinant bacteria and use thereof

Publication Date: 2025.05.13 CHANGSHA LVYE BIOTECHNOLOGY CO LTD

AI summary

A recombinant vector containing the immunogenic protein of African swine fever virus, a recombinant bacterium and use thereof, and relates to the technical field of gene recombination. The recombinant vector can be used to construct a recombinant Lactobacillus expressing the immunogenic protein of African swine fever virus, and after mixing the Lactobacillus solution that can secrete protein p72 and protein p54, respectively, an oral live bacterial preparation for preventing African swine fever can be prepared. The oral live bacteria preparation prepared by the disclosure can safely, effectively and quickly prevent the infection of African swine fever virus to pigs, and does not contain an immune process.